Skip to main content Skip to footer
Algernon Pharmaceuticals Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

Videos/Articles

MedicalGold.ca – Algernon Rapidly Advances Clinical Trials For Two Lead Programs
Aug 17, 2022

MedicalGold.ca – Algernon Rapidly Advances Clinical Trials For Two Lead Programs

Pulmonary Fibrosis News – NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial
Jul 20, 2022

Pulmonary Fibrosis News – NP-120, Potential IPF Treatment, Stabilizes Lung Function in Trial

Streetwise Reports – Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity
Jul 20, 2022

Streetwise Reports – Patients in Algernon’s Phase 2a Study Show Improved Lung Capacity

Proactive Investors Interview – Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage
Jul 18, 2022

Proactive Investors Interview – Algernon Pharmaceuticals Study of Ifenprodil for the Treatment of IPF and Chronic Cough Reaches Key Stage

Streetwise Reports – Can the Psychedelic Drug DMT Take Algernon to the Next Level?
Jul 14, 2022

Streetwise Reports – Can the Psychedelic Drug DMT Take Algernon to the Next Level?

Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251
Jul 11, 2022

Algernon Pharmaceuticals Provides Update on Chronic Kidney Disease Research Program with NP-251

Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September 2022
Jul 7, 2022

Algernon Pharmaceuticals Phase 1 DMT Stroke Study Will Start in September 2022

Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program
Apr 5, 2022

Business Television – Algernon Pharmaceuticals and the DMT/Stroke Clinical Program

Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study
Jan 28, 2022

Streetwise Live! – Algernon is Awaiting Approval for a Phase 1 DMT Human Stroke Study

Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property
Jan 24, 2022

Proactive Investors Interview – Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy for DMT Intellectual Property

Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study
Jan 19, 2022

Proactive Investors Interview – Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Stroke Study

This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion
Jan 17, 2022

This Pharmaceutical Company Has a Brilliant Concept – An Expert Opinion

Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA
Jan 14, 2022

Algernon Pharmaceuticals Ifenprodil Chronic Cough Study Receives Positive Feedback from U.S. FDA

Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes
Jan 4, 2022

Streetwise Reports – Algernon Pharmaceuticals Looks to U.S. for Help Fighting Strokes

Market One – Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment
Nov 25, 2021

Market One – Rethinking DMT: Algernon Pharmaceuticals’ Novel Approach to Stroke Treatment

Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study
Nov 24, 2021

Proactive Investors Interview – Algernon Pharmaceuticals Receives a Positive Response from U.S. FDA on SCLC Study

Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 4
Nov 19, 2021

Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 4

Proactive Investors Interview – Algernon Pharmaceuticals Receives Positive Feedback On Its Planned Phase 1/2a DMT Human Stroke Stud
Nov 19, 2021

Proactive Investors Interview – Algernon Pharmaceuticals Receives Positive Feedback On Its Planned Phase 1/2a DMT Human Stroke Stud

Algernon Presents Psychiatrist and Author Rick Strassman, MD on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD
Nov 13, 2021

Algernon Presents Psychiatrist and Author Rick Strassman, MD on a Special BioPub Webcast Hosted by Dr. KSS, MD, PhD

Proactive Investors Interview – Algernon Pharmaceuticals Establishes Optimum Treatment Period for DMT
Nov 1, 2021

Proactive Investors Interview – Algernon Pharmaceuticals Establishes Optimum Treatment Period for DMT

Powerplay by the Market Herald Interviews Christopher J. Moreau, CEO
Oct 9, 2021

Powerplay by the Market Herald Interviews Christopher J. Moreau, CEO

DMT Increases Growth of Rat Neurons by 40 Percent, New Data Shows
Sep 27, 2021

DMT Increases Growth of Rat Neurons by 40 Percent, New Data Shows

Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 3
Sep 23, 2021

Upfront with Algernon Pharmaceuticals CEO Chistopher J Moreau – Episode 3

The Dales Report – Preclinical Study Shows Microdoses of DMT Increased Growth of Neurons
Sep 13, 2021

The Dales Report – Preclinical Study Shows Microdoses of DMT Increased Growth of Neurons

Upfront with Algernon Pharmaceuticals CEO Christopher J. Moreau – Episode 2
Sep 11, 2021

Upfront with Algernon Pharmaceuticals CEO Christopher J. Moreau – Episode 2

Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40%
Sep 7, 2021

Proactive Investors Interview – Algernon Pharmaceutical’s Preclinical Study of DMT for Stroke Confirms Growth of Neurons by 40%

Psychedelic Finance – Interview with Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
Sep 7, 2021

Psychedelic Finance – Interview with Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals

Upfront With Algernon Pharmaceuticals CEO
Aug 24, 2021

Upfront With Algernon Pharmaceuticals CEO

Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke
Jul 9, 2021

Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke

Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled
Jul 7, 2021

Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled

Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke
Jun 22, 2021

Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke

Weekend Dispensary – Could the ‘spirit molecule’ be a treatment option for stroke?
May 22, 2021

Weekend Dispensary – Could the ‘spirit molecule’ be a treatment option for stroke?

Psychedelic Finance – Interview with Dr. Rick Strassman | DMT Stroke Program Consultant, Algernon Pharmaceuticals
May 21, 2021

Psychedelic Finance – Interview with Dr. Rick Strassman | DMT Stroke Program Consultant, Algernon Pharmaceuticals

Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback
May 17, 2021

Algernon Pharmaceutical’s DMT Clinical Research Program for Stroke Receives Positive FDA Feedback

PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau
May 13, 2021

PRMediaNow Algernon Pharmaceuticals Update with CEO Christopher Moreau

Proactive Interview regarding 50% enrollment into the IPF/Chronic Cough
May 12, 2021

Proactive Interview regarding 50% enrollment into the IPF/Chronic Cough

rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Next Pagearrow_forward
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
©2025 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap